Drug Approval | July 24, 2024
Shilpa Biologicals receives registration approval for Adalimumab from Morocco, MoH
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.
Diclofenac Sodium and Misoprostol Delayed Release Tablets USP, 50mg/200 mcg and 75mg/200 mcg had annual sales of USD 13 mn in the United States
The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable
The investment will include facility and equipment improvements and the addition of 60 full-time positions in 3M manufacturing facilities in Europe.
New York State’s largest health system adopts Philips patient monitoring platform to drive integration and innovation for a better patient and staff experience and improved outcomes
Tofacitinib Tablets, 5 mg and 10 mg had annual sales of US $900 million in the United States (IQVIA MAT December 2022)
Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions
The proposed initiative is conceptualised with an objective to identify, support, and promote innovative research ideas in healthcare research
Subscribe To Our Newsletter & Stay Updated
